{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:39:35Z","timestamp":1787020775587,"version":"build-2736575974"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/X020258\/1"],"award-info":[{"award-number":["MR\/X020258\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. National Institutes of Health","doi-asserted-by":"crossref","award":["NIH UM1 AI068617"],"award-info":[{"award-number":["NIH UM1 AI068617"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This systematic review and meta-analysis assessed viral suppression among adults receiving WHO-recommended first-line dolutegravir-based ART in programmatic settings in low- and middle-income countries (LMICs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic search of Ovid MEDLINE, Embase, and major HIV conferences (IAS, AIDS, and CROI) from January 2019 to September 2024 identified cohort and cross-sectional studies reporting viral suppression among adults receiving WHO-recommended first-line dolutegravir-based ART in LMICs. Studies with follow-ups\u2009\u2264\u20094 months or using non-WHO-recommended regimens were excluded. Pooled estimates were calculated using random-effects meta-analysis. Sensitivity analyses excluded outliers. Subgroup analyses distinguished adults initiating versus transitioning to dolutegravir-based ART. Both on-treatment and intention-to-treat outcomes were assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Twenty-two studies (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200947 to 50,742) from 13 countries were included. On-treatment pooled viral suppression was 95% (95% CI: 91\u201397%, I\u00b2= 96%) at six months, 96% (94\u201398%, I\u00b2 = 97%) at 12 months, and 98% (96\u201399%, I\u00b2 = 94%) at 24 months. Sensitivity analysis removing outliers decreased heterogeneity and slightly lowered the 6\u2011month estimate (to 94%), with negligible change at 12 months. At 6 months, viral suppression was higher in those transitioning than initiating ART (98% vs. 94%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01), with similar rates at 12 months (97%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.67). The pooled intention-to-treat 12-month viral suppression rate was 89% (82\u201393%, I\u00b2 = 95%), with no significant difference by ART status (initiating 86% vs. transitioning 91%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.44).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Adults retained in care receiving WHO-recommended first-line dolutegravir-based ART achieved viral suppression rates of \u2265\u200995% up to two years. These findings align with the UNAIDS 95% suppression target and reinforce the role of dolutegravir-based regimens in ending HIV as a public health threat.<\/jats:p>\n                    <jats:p>\n                      <jats:italic>Trial registration:<\/jats:italic>\n                      CRD42024557769.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12981-025-00788-8","type":"journal-article","created":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T09:09:10Z","timestamp":1758877750000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["High HIV viral suppression among adults receiving WHO-recommended first-line dolutegravir-based antiretroviral therapy in low- and middle-income countries: a systematic review and meta-analysis of programmatic evidence"],"prefix":"10.1186","volume":"22","author":[{"given":"Amalia","family":"Gir\u00f3n-Callejas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolando","family":"Lorenzana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Pickles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth","family":"Inzaule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheilee","family":"Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Vrinten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,26]]},"reference":[{"key":"788_CR1","unstructured":"Global HIV, AIDS statistics\u2014Fact sheet: The Joint United Nations Programme on HIV\/AIDS (UNAIDS). 2024. https:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/UNAIDS_FactSheet_en.pdf"},{"key":"788_CR2","unstructured":"Global Burden of Disease: Compare the cause of death in low- and middle-income countries: Institute for Health Metrics and Evaluation (IHME). 2019 [Available from: http:\/\/ihmeuw.org\/65of"},{"key":"788_CR3","first-page":"144","volume-title":"Viral hepatitis and STI prevention, diagnosis, treatment and care for key populations","author":"Consolidated guidelines on HIV","year":"2022","unstructured":"Consolidated guidelines on HIV. Viral hepatitis and STI prevention, diagnosis, treatment and care for key populations. Geneva: World Health Organization; 2022. p. 144."},{"issue":"10400","key":"788_CR4","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/S0140-6736(23)00877-2","volume":"402","author":"LN Broyles","year":"2023","unstructured":"Broyles LN, Luo R, Boeras D, Vojnov L. The risk of sexual transmission of HIV in individuals with low-level HIV viraemia: a systematic review. Lancet. 2023;402(10400):464\u201371.","journal-title":"Lancet"},{"key":"788_CR5","unstructured":"Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. Geneva: World Health Organization; 2021."},{"key":"788_CR6","doi-asserted-by":"publisher","first-page":"100573","DOI":"10.1016\/j.eclinm.2020.100573","volume":"28","author":"S Kanters","year":"2020","unstructured":"Kanters S, Vitoria M, Zoratti M, Doherty M, Penazzato M, Rangaraj A, et al. Comparative efficacy, tolerability and safety of dolutegravir and efavirenz 400 mg among antiretroviral therapies for first-line HIV treatment: a systematic literature review and network meta-analysis. EClinicalMedicine. 2020;28:100573.","journal-title":"EClinicalMedicine"},{"key":"788_CR7","unstructured":"The path that ends AIDS: UNAIDS Global AIDS Update. 2023. Geneva: The Joint United Nations Programme on HIV\/AIDS (UNAIDS); 2023. p. 195."},{"key":"788_CR8","unstructured":"2024 HIV MARKET REPORT. Clinton Health Access Initiative; 2024."},{"key":"788_CR9","unstructured":"Sustainable Development Goal 3. Ensure healthy lives and promote well-being for all at all ages: United Nations. https:\/\/sdgs.un.org\/goals\/goal3."},{"key":"788_CR10","unstructured":"Prevailing against pandemics by putting people at the centre. Geneva: Joint United Nations Programme on HIV\/AIDS (UNAIDS); 2020. p. 87."},{"key":"788_CR11","unstructured":"Sustainable Development Goals. Goal 3: Ensure healthy lives and promote well-being for all at all ages.: United Nations. https:\/\/sdgs.un.org\/goals\/goal3#targets_and_indicators."},{"issue":"9","key":"788_CR12","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1097\/QAD.0000000000002523","volume":"34","author":"EM Frijters","year":"2020","unstructured":"Frijters EM, Hermans LE, Wensing AMJ, Devill\u00e9 W, Tempelman HA, De Wit JBF. Risk factors for loss to follow-up from antiretroviral therapy programmes in low-income and middle-income countries. AIDS. 2020;34(9):1261\u201388.","journal-title":"AIDS"},{"issue":"1","key":"788_CR13","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/QAI.0000000000000553","volume":"69","author":"MP Fox","year":"2015","unstructured":"Fox MP, Rosen S. Retention of adult patients on antiretroviral therapy in low- and middle-income countries: systematic review and meta-analysis 2008\u20132013. J Acquir Immune Defic Syndr. 2015;69(1):98\u2013108.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"3","key":"788_CR14","doi-asserted-by":"publisher","first-page":"e1003583","DOI":"10.1371\/journal.pmed.1003583","volume":"18","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. PLoS Med. 2021;18(3):e1003583\u2013e.","journal-title":"PLoS Med"},{"key":"788_CR15","unstructured":"Giron-Callejas A, Lorenzana R, Vrinten C, Pickles M, Inzaule S, Jordan MR et al. Prevalence of HIV viral load suppression among adults receiving WHO-recommended first-line dolutegravir-based antiretroviral therapy in low- and middle-income countries CRD42024557769: PROSPERO; 2024. https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?ID=CRD42024557769. Accessed 18 Jun 2024."},{"key":"788_CR16","unstructured":"World Bank Country and Lending Groups Country Classification: The World Bank. 2024. https:\/\/datahelpdesk.worldbank.org\/knowledgebase\/articles\/906519."},{"key":"788_CR17","unstructured":"Updated recommendations on first-line and. supplement to the 2016 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Geneva: World Health Organization; 2018. p. 79. second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV: interim guidelines."},{"key":"788_CR18","unstructured":"Covidence systematic review software. Veritas Health Innovation."},{"key":"788_CR19","volume-title":"R: A Language and environment for statistical computing","author":"Team RC","year":"2022","unstructured":"Team RC. R: A Language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2022."},{"issue":"4","key":"788_CR20","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","volume":"22","author":"S Balduzzi","year":"2019","unstructured":"Balduzzi S, R\u00fccker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health. 2019;22(4):153\u201360.","journal-title":"Evid Based Ment Health"},{"key":"788_CR21","first-page":"16","volume-title":"Of HIV viral suppression in improving individual health and reducing transmission: policy brief","author":"The role","year":"2023","unstructured":"The role. Of HIV viral suppression in improving individual health and reducing transmission: policy brief. Geneva: World Health Organization; 2023. p. 16."},{"key":"788_CR22","unstructured":"People living with HIV who have suppressed viral loads Indicator Registry: Joint United Nations Programme on HIV\/AIDS (UNAIDS). 2024. https:\/\/indicatorregistry.unaids.org\/indicator\/people-living-hiv-who-have-suppressed-viral-loads#:~:text=Viral%20suppression%20is%20defined%20as,95%2D95%2D95%20target."},{"key":"788_CR23","doi-asserted-by":"crossref","unstructured":"Harrer M, Cuijpers P, Furukawa TA, Ebert DD. Doing meta-analysis with R: a hands-on guide. 1st ed. Boca Raton, FL and London: Chapman & Hall\/CRC Press; 2021.","DOI":"10.1201\/9781003107347"},{"issue":"3","key":"788_CR24","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1097\/XEB.0000000000000054","volume":"13","author":"Z Munn","year":"2015","unstructured":"Munn Z, Moola S, Lisy K, Riitano D, Tufanaru C. Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data. Int J Evid Based Healthc. 2015;13(3):147\u201353.","journal-title":"Int J Evid Based Healthc"},{"key":"788_CR25","doi-asserted-by":"crossref","unstructured":"Moola S, Munn Z, Tufanaru C, Aromataris E, Sears K, Sfetcu R, et al. In: Aromataris E, Munn Z, editors. Chapter 7: systematic reviews of etiology and risk. JBI Manual for Evidence Synthesis: JBI; 2020.","DOI":"10.46658\/JBIRM-17-06"},{"key":"788_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph19031085","author":"RT Buju","year":"2022","unstructured":"Buju RT, Akilimali PZ, Kamangu EN, Mesia GK, Kayembe JMN, Situakibanza HN. Predictors of viral non-suppression among patients living with HIV under dolutegravir in Bunia, Democratic Republic of Congo: a prospective cohort study. Int J Environ Res Public Health. 2022. https:\/\/doi.org\/10.3390\/ijerph19031085.","journal-title":"Int J Environ Res Public Health"},{"issue":"2","key":"788_CR27","first-page":"431","volume":"31","author":"JB Marc","year":"2023","unstructured":"Marc JB, Pierre S, Rivera V, Abigail Z, Montreuil D, Homeus F, et al. A model of successful ART initiation in the context of massive civil unrest in Haiti. Top Antiviral Med. 2023;31(2):431.","journal-title":"Top Antiviral Med"},{"key":"788_CR28","doi-asserted-by":"publisher","unstructured":"Brites C, Lacerda M, Eduardo S, Bay M, Pinto G, Azevedo P et al. Survival in advanced AIDS patients treated with Efavirenz or dolutegravir in Brazil: a multicenter, observational study[conference abstract]. J Int AIDS Soc. 2022;25(Suppl 3):OAB0305. https:\/\/doi.org\/10.1002\/jia2.25935.","DOI":"10.1002\/jia2.25935"},{"issue":"5","key":"788_CR29","doi-asserted-by":"publisher","first-page":"720","DOI":"10.3390\/v16050720","volume":"16","author":"OT Bareng","year":"2024","unstructured":"Bareng OT, Moyo S, Mudanga M, Sebina K, Koofhethile CK, Choga WT, et al. Low-level viremia among adults living with HIV on dolutegravir-based first-line antiretroviral therapy is a predictor of virological failure in Botswana. Viruses. 2024;16(5):720. https:\/\/doi.org\/10.3390\/v16050720.","journal-title":"Viruses"},{"key":"788_CR30","doi-asserted-by":"publisher","unstructured":"McCluskey SM, Muyindike WR, Nanfuka V, Omoding D, Komukama N, Barigye IT et al. Population effectiveness of dolutegravir implementation in Uganda\u2014a prospective observational cohort study (DISCO): 48-week results. J Infect Dis. 2024;230(3):e622\u201330. https:\/\/doi.org\/10.1093\/infdis\/jiae260.","DOI":"10.1093\/infdis\/jiae260"},{"issue":"8","key":"788_CR31","doi-asserted-by":"publisher","first-page":"e544","DOI":"10.1016\/S2352-3018(22)00136-9","volume":"9","author":"B Schramm","year":"2022","unstructured":"Schramm B, Temfack E, Descamps D, Nicholas S, Peytavin G, Bitilinyu-Bangoh JE, et al. Viral suppression and HIV-1 drug resistance 1 year after pragmatic transitioning to dolutegravir first-line therapy in malawi: a prospective cohort study. Lancet HIV. 2022;9(8):e544\u201353.","journal-title":"Lancet HIV"},{"issue":"1","key":"788_CR32","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.1038\/s41598-024-53282-y","volume":"14","author":"T Gebremedhin","year":"2024","unstructured":"Gebremedhin T, Aynalem M, Adem M, Geremew D, Aleka Y, Kiflie A. Dolutegravir based therapy showed CD4\u2009+\u2009T cell count recovery and viral load suppression among ART naive people living with HIV AIDS: a pilot evaluation. Sci Rep. 2024;14(1):3297.","journal-title":"Sci Rep"},{"issue":"6","key":"788_CR33","first-page":"e40139","volume":"15","author":"PR Mahale","year":"2023","unstructured":"Mahale PR, Patel BS, Kasmani N. Treatment outcomes of dolutegravir- versus efavirenz-based highly active antiretroviral therapy regimens among treatment-naive people living with HIV. Cureus. 2023;15(6):e40139.","journal-title":"Cureus"},{"issue":"8","key":"788_CR34","doi-asserted-by":"publisher","first-page":"e0238052","DOI":"10.1371\/journal.pone.0238052","volume":"15","author":"A Correa","year":"2020","unstructured":"Correa A, Monteiro P, Calixto F, Batista JAL, de Alencar Ximenes RA, Montarroyos UR. Dolutegravir: virologic response and tolerability of initial antiretroviral regimens for adults living with HIV. PLoS ONE. 2020;15(8):e0238052.","journal-title":"PLoS ONE"},{"key":"788_CR35","doi-asserted-by":"crossref","unstructured":"Mehari EA, Muche EA, Gonete KA. Virological suppression and its associated factors of dolutegravir based regimen in a resource-limited setting: an observational retrospective study in Ethiopia. HIV\/AIDS (Auckland NZ). 2021;13(101515943):709\u201317.","DOI":"10.2147\/HIV.S316776"},{"key":"788_CR36","unstructured":"Avalos A, Melamu P, Brown D, Vannappaggari V, Gaolathe T, Lesego K et al. Similar 12 & 24 month preliminary outcomes for TRU\/DTG and TDF\/FTC\/EFV regimens in Botswana: The Botswana Epidemiological ART Treatment Cohort Study (The BEAT). IAS. 2019; Mexico City 2019."},{"key":"788_CR37","unstructured":"Skrivankova VW, Huwa J, Muula G, Chiwaya GD, Banda E, Buleya S et al. Viremia and drug resistance 2 years after routine switching to dolutegravir-based first-line ART. CROI. 2024; Boston 2024."},{"issue":"10","key":"788_CR38","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1097\/QAD.0000000000002254","volume":"33","author":"MV Meireles","year":"2019","unstructured":"Meireles MV, Pascom ARP, Duarte EC, McFarland W. Comparative effectiveness of first-line antiretroviral therapy: results from a large real-world cohort after the implementation of dolutegravir. AIDS. 2019;33(10):1663\u20138.","journal-title":"AIDS"},{"key":"788_CR39","unstructured":"McCluskey S, Shazi G, Dayi N, Stuckwisch A, Aung TN, Hedt-Gauthier B, et al. 48-Week outcomes after programmatic transition to dolutegravir in South Africa. CROI; 2024. Boston 2024."},{"issue":"9","key":"788_CR40","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1093\/cid\/civ556","volume":"61","author":"TS Boender","year":"2015","unstructured":"Boender TS, Sigaloff KC, McMahon JH, Kiertiburanakul S, Jordan MR, Barcarolo J, et al. Long-term virological outcomes of first-line antiretroviral therapy for HIV-1 in low- and middle-income countries: a systematic review and meta-analysis. Clin Infect Dis. 2015;61(9):1453\u201361.","journal-title":"Clin Infect Dis"},{"issue":"11","key":"788_CR41","doi-asserted-by":"publisher","first-page":"e510","DOI":"10.1016\/S2352-3018(16)30091-1","volume":"3","author":"S Kanters","year":"2016","unstructured":"Kanters S, Vitoria M, Doherty M, Socias ME, Ford N, Forrest JI, et al. Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis. Lancet HIV. 2016;3(11):e510\u201320.","journal-title":"Lancet HIV"},{"key":"788_CR42","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.meegid.2016.08.031","volume":"46","author":"DS Clutter","year":"2016","unstructured":"Clutter DS, Jordan MR, Bertagnolio S, Shafer RW. HIV-1 drug resistance and resistance testing. Infect Genet Evolution: J Mol Epidemiol Evolutionary Genet Infect Dis. 2016;46:292\u2013307.","journal-title":"Infect Genet Evolution: J Mol Epidemiol Evolutionary Genet Infect Dis"},{"issue":"8","key":"788_CR43","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.26350","volume":"27","author":"Z Wagner","year":"2024","unstructured":"Wagner Z, Wang Z, Stecher C, Karamagi Y, Odiit M, Haberer JE, et al. The association between adherence to antiretroviral therapy and viral suppression under dolutegravir-based regimens: an observational cohort study from Uganda. J Int AIDS Soc. 2024;27(8): e26350.","journal-title":"J Int AIDS Soc"},{"issue":"2","key":"788_CR44","doi-asserted-by":"publisher","first-page":"e0263663","DOI":"10.1371\/journal.pone.0263663","volume":"17","author":"S Muhula","year":"2022","unstructured":"Muhula S, Gachohi J, Kombe Y, Karanja S. Interventions to improve early retention of patients in antiretroviral therapy programmes in sub-Saharan Africa: a systematic review. PLoS One. 2022;17(2):e0263663.","journal-title":"PLoS One"},{"issue":"11","key":"788_CR45","doi-asserted-by":"publisher","first-page":"e1003836","DOI":"10.1371\/journal.pmed.1003836","volume":"18","author":"CA Bulstra","year":"2021","unstructured":"Bulstra CA, Hontelez JAC, Otto M, Stepanova A, Lamontagne E, Yakusik A, et al. Integrating HIV services and other health services: a systematic review and meta-analysis. PLoS Med. 2021;18(11):e1003836.","journal-title":"PLoS Med"},{"issue":"10","key":"788_CR46","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/j.jiph.2022.08.012","volume":"15","author":"LE Pugh","year":"2022","unstructured":"Pugh LE, Roberts JS, Viswasam N, Hahn E, Ryan S, Turpin G, et al. Systematic review of interventions aimed at improving HIV adherence to care in low- and middle-income countries in Sub-Saharan Africa. J Infect Public Health. 2022;15(10):1053\u201360.","journal-title":"J Infect Public Health"},{"issue":"3","key":"788_CR47","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.2540","volume":"34","author":"IH Mosha","year":"2024","unstructured":"Mosha IH, Nyondo GG, Munishi CG, Njiro BJ, Bwire GM. Prevalence and factors associated with viral non-suppression in people living with HIV receiving antiretroviral therapy in sub-Saharan Africa: a systematic review and meta-analysis. Rev Med Virol. 2024;34(3): e2540.","journal-title":"Rev Med Virol"},{"issue":"12","key":"788_CR48","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1097\/QAD.0000000000001845","volume":"32","author":"M Vitoria","year":"2018","unstructured":"Vitoria M, Hill A, Ford N, Doherty M, Clayden P, Venter F, et al. The transition to dolutegravir and other new antiretrovirals in low-income and middle-income countries: what are the issues? AIDS. 2018;32(12):1551\u201361.","journal-title":"AIDS"},{"key":"788_CR49","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae261","author":"VW Skrivankova","year":"2024","unstructured":"Skrivankova VW, Huwa J, Muula G, Chiwaya GD, Banda E, Buleya S, et al. Virologic failure and drug resistance after programmatic switching to dolutegravir-based first-line antiretroviral therapy in Malawi and Zambia. Clin Infect Dis. 2024. https:\/\/doi.org\/10.1093\/cid\/ciae261.","journal-title":"Clin Infect Dis"},{"key":"788_CR50","first-page":"46","volume-title":"\u2013 brief report 2024","author":"HIV drug resistance","year":"2024","unstructured":"HIV drug resistance. \u2013 brief report 2024. Geneva: World Health Organization; 2024. p. 46."},{"issue":"1","key":"788_CR51","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1186\/s12889-022-13504-2","volume":"22","author":"MD Pham","year":"2022","unstructured":"Pham MD, Nguyen HV, Anderson D, Crowe S, Luchters S. Viral load monitoring for people living with HIV in the era of test and treat: progress made and challenges ahead - a systematic review. BMC Public Health. 2022;22(1):1203.","journal-title":"BMC Public Health"},{"key":"788_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(25)00074-8","author":"DT Brink","year":"2025","unstructured":"Brink DT, Martin-Hughes R, Bowring AL, Wulan N, Burke K, Tidhar T, et al. Impact of an international HIV funding crisis on HIV infections and mortality in low-income and middle-income countries: a modelling study. Lancet HIV. 2025. https:\/\/doi.org\/10.1016\/S2352-3018(25)00074-8.","journal-title":"Lancet HIV"},{"key":"788_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103233","author":"JAC Hontelez","year":"2025","unstructured":"Hontelez JAC, Goymann H, Berhane Y, Bhattacharjee P, Bor J, Chabata ST, et al. The impact of the PEPFAR funding freeze on HIV deaths and infections: a mathematical modelling study of seven countries in sub-Saharan Africa. eClinMed. 2025. https:\/\/doi.org\/10.1016\/j.eclinm.2025.103233.","journal-title":"eClinMed"},{"issue":"1 SUPPL","key":"788_CR54","first-page":"187","volume":"30","author":"C Kityo","year":"2022","unstructured":"Kityo C, McCarthy C, Hughes M, Godfrey C, Wallis C, Parikh U, et al. Efficacy of Tenofovir-Lamivudine-Dolutegravir for initial and First-Line switch ART. Top Antiviral Med. 2022;30(1 SUPPL):187.","journal-title":"Top Antiviral Med"},{"key":"788_CR55","doi-asserted-by":"publisher","DOI":"10.3390\/tropicalmed8080391","author":"A Gemechu","year":"2023","unstructured":"Gemechu A, Mihret A, Atire FA, Aseffa A, Howe R, Seyoum B, et al. Virological non-suppression among newly diagnosed HIV-positive individuals on dolutegravir-based antiretroviral treatment in Eastern Ethiopia: follow-up study. Trop Med Infect Dis. 2023. https:\/\/doi.org\/10.3390\/tropicalmed8080391.","journal-title":"Trop Med Infect Dis"},{"issue":"1","key":"788_CR56","first-page":"142","volume":"29","author":"S McCluskey","year":"2021","unstructured":"McCluskey S, Muyindike W, Omoding D, Masette G, Stuckwisch A, Hedt-Gauthier B, et al. Effectiveness of the dolutegravir transition in uganda: disco cohort week-24 results. Top Antiviral Med. 2021;29(1):142.","journal-title":"Top Antiviral Med"},{"issue":"2","key":"788_CR57","first-page":"229","volume":"31","author":"SM McCluskey","year":"2023","unstructured":"McCluskey SM, Muyindike W, Lessells R, Giandhari J, Nanfuka V, Omoding D, et al. Incidence of acquired integrase resistance after transition to dolutegravir in Uganda. Top Antiviral Med. 2023;31(2):229.","journal-title":"Top Antiviral Med"},{"issue":"5","key":"788_CR58","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1097\/QAD.0000000000003830","volume":"38","author":"V Kouamou","year":"2024","unstructured":"Kouamou V, Washaya T, Mapangisana T, Ndhlovu CE, Manasa J. Virological, weight, and drug resistance outcomes among patients initiating a dolutegravir-based first-line antiretroviral therapy regimen in Zimbabwe. AIDS. 2024;38(5):689\u201396.","journal-title":"AIDS"},{"issue":"9","key":"788_CR59","first-page":"72","volume":"71","author":"D Sengupta","year":"2023","unstructured":"Sengupta D, Ghosh S, Pain S, Chatterjee N. Efficacy and tolerability of tenofovir\/lamivudine\/dolutegravir among antiretroviral therapy Naive human immunodeficiency virus infected patients of a tertiary care center in Eastern India. J Assoc Physicians India. 2023;71(9):72\u20134.","journal-title":"J Assoc Physicians India"},{"issue":"1","key":"788_CR60","doi-asserted-by":"publisher","first-page":"31","DOI":"10.4103\/ijstd.IJSTD_34_20","volume":"42","author":"AK Patel","year":"2021","unstructured":"Patel AK, Patel KK, Pujari S, Patel JK, Kumar A. Virological outcome and frequency of low-level viremia in patients receiving generic dolutegravir-containing regimen at a large tertiary care clinic in Western India. Indian J Sex Transm Dis AIDS. 2021;42(1):31\u20137.","journal-title":"Indian J Sex Transm Dis AIDS"},{"issue":"101548923","key":"788_CR61","doi-asserted-by":"publisher","first-page":"1122018","DOI":"10.3389\/fphar.2023.1122018","volume":"14","author":"MM Milward de Azevedo Meiners","year":"2023","unstructured":"Milward de Azevedo Meiners MM, Araujo Cruz I, de Toledo MI. Adherence to antiretroviral therapy and viral suppression: analysis of three periods between 2011 and 2017 at an HIV-AIDS center, Brazil. Front Pharmacol. 2023;14(101548923):1122018.","journal-title":"Front Pharmacol"},{"issue":"101281800","key":"788_CR62","doi-asserted-by":"publisher","first-page":"eAO0156","DOI":"10.31744\/einstein_journal\/2023AO0156","volume":"21","author":"CCP Silva GJd, Mendicino","year":"2023","unstructured":"Silva GJd, Mendicino CCP, Padua CAMd, Tupinambas U. Suppression of HIV in the first 12 months of antiretroviral therapy: a comparative analysis of dolutegravir- and efavirenz-based regimens. Einstein (Sao Paulo Brazil). 2023;21(101281800):eAO0156.","journal-title":"Einstein (Sao Paulo Brazil)"},{"issue":"1","key":"788_CR63","doi-asserted-by":"publisher","DOI":"10.3390\/v15010018","volume":"15","author":"ENJ Semengue","year":"2022","unstructured":"Semengue ENJ, Fokam J, Etame N-K, Molimbou E, Chenwi CA, Takou D, et al. Dolutegravir-based regimen ensures high virological success despite prior exposure to Efavirenz-based first-LINE ART in Cameroon: an evidence of a successful transition model. Viruses. 2022;15(1): 18.","journal-title":"Viruses"}],"container-title":["AIDS Research and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-025-00788-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12981-025-00788-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-025-00788-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T09:09:19Z","timestamp":1758877759000},"score":1,"resource":{"primary":{"URL":"https:\/\/aidsrestherapy.biomedcentral.com\/articles\/10.1186\/s12981-025-00788-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,26]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["788"],"URL":"https:\/\/doi.org\/10.1186\/s12981-025-00788-8","relation":{},"ISSN":["1742-6405"],"issn-type":[{"value":"1742-6405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,26]]},"assertion":[{"value":"12 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"91"}}